These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35292330)

  • 1. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.
    Cenci MA; Skovgård K; Odin P
    Neuropharmacology; 2022 Jun; 210():109027. PubMed ID: 35292330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatments for levodopa-induced motor complications.
    Rascol O; Perez-Lloret S; Ferreira JJ
    Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
    Sebastianutto I; Cenci MA
    Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
    Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin 5-HT
    Pinna A; Parekh P; Morelli M
    Neuropharmacology; 2023 Mar; 226():109411. PubMed ID: 36608814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
    Frouni I; Huot P
    Neurodegener Dis Manag; 2022 Aug; 12(4):203-214. PubMed ID: 35587024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.
    Cerri S; Siani F; Blandini F
    Expert Opin Investig Drugs; 2017 Jul; 26(7):777-791. PubMed ID: 28535734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
    Schaeffer E; Pilotto A; Berg D
    CNS Drugs; 2014 Dec; 28(12):1155-84. PubMed ID: 25342080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interactions between adenosine A
    Pinna A; Serra M; Marongiu J; Morelli M
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
    Jing XZ; Yuan XZ; Luo X; Zhang SY; Wang XP
    Curr Neuropharmacol; 2023; 21(8):1806-1826. PubMed ID: 35193486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
    Iravani MM; Jenner P
    J Neural Transm (Vienna); 2011 Dec; 118(12):1661-90. PubMed ID: 21881839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.